Renovaro Biosciences Announces Results of Special Meeting of Shareholders
25 Janeiro 2024 - 2:45PM
Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a
biotechnology corporation focusing on cell, gene, and
immunotherapy, announced today the results of the Company’s Special
Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.
All of the matters put forward before the Company's shareholders
for consideration and approval, as set out in the Company's
definitive proxy statement dated January 3, 2024, were
approved by the requisite number of votes cast at the meeting.
For complete results on all matters voted on at the meeting,
please consult the Company's Form 8-K which will be filed on EDGAR
at www.sec.gov/edgar.
ABOUT THE COMPANYRenovaro has developed
advanced cell, gene, and immunotherapy platforms designed to renew
the body’s natural tumor-fighting capabilities against cancer and
infectious diseases. For more information on Renovaro, go to their
website at www.renovarobio.com.
Contact: ir@renovarobio.comSource: Renovaro
Bioscience Inc.
Renovaro (NASDAQ:RENB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Renovaro (NASDAQ:RENB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024